Johnson & Johnson announced sales of $18.5 billion on July 19, 2016 for the second quarter of 2016, an increase of 3.9% as compared to the second quarter of 2015 based on the financial success of two dangerous drugs — Xarelto, an anticoagulant, and Invokana, a type 2 diabetes therapy.
Federal Xarelto Litigation is consolidated before US District Judge Eldon Fallon in MDL 2592 and the state litigation is consolidated in the Philadelphia Court of Common Pleas before Judge Arnold New. In the state MDL Judge New has elected to allow “Efficacy Claims” to be filed in that MDL in addition to claims related to uncontrolled bleeding. Judge Fallon has yet to follow suit and may not.
In Q2, Xarelto sales jumped 26% year over year to $594 million. That performance will likely keep it as the second-best-selling drug in a class of next-generation anticoagulants known as factor Xa inhibitors, according to the Motley Fool. Factor Xa’s like Xarelto are taking away market share from Warfarin, which has been the dominant anticoagulant over the past 50 years, the investment website says.
While Xarelto’s growth remains strong, sales growth did slide slightly from 29% in Q1. The Motley Fool suggests that the factor Xa from Pfizer and Bristol-Myers Squibb, Eliquis, continues to win share more quickly than Xarelto. In Q1, Eliquis sales more than doubled year-over-year to $734 million.